Verily (formerly Google Life Sciences) is a subsidiary of Google's parent company, Alphabet. The company is devoted to the study of life sciences which operates as a life sciences research and engineering organization.
Verily is focused on using technology to better understand health, as well as prevent, detect, and manage disease.
Verily was formerly a division of Google X, until 10 August 2015 when Sergey Brin announced that the organization would become an independent subsidiary of Alphabet Inc. This restructuring process was completed on October 2, 2015. On December 7, 2015, Google Life Sciences was renamed Verily.
Verily develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease.
Verily partners with leading life sciences, medical device and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale.
Verily's leaders possess a shared purpose and vision to address some of the most daunting challenges in healthcare. Verily is putting technology and data science to work on diseases and other global health problems that stand in the way of people enjoying healthier, happier lives.
Verily is backed by Alphabet, Silver Lake Partners, Temasek Holdings and Ontario Teachers' Pension Plan. The company raised $700M in a new round on Dec 17, 2020. This brings Verily's total funding to $2.5B to date. Verily was valued at $1.6B in Jan 26, 2017. Their recent valuation wasn't disclosed. Verily has also made over 5 investments totaling more than $260M, including a $165M investment in Oscar Health on Mar 27, 2018.